In a longitudinal analysis of patients with metastatic melanoma who received sequential therapies targeting CTLA-4, then PD-1 upon disease progression, researchers have discovered that high copy-number loss in recurrent regions of the tumor genome is associated with resistance to immune checkpoint blockade.
http://ift.tt/2oZG5CM
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου